RecruitingPhase 2NCT06856213
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Principal Investigator
- Santiago Cabezas, M.D., Ph.D.Hospital San Carlos, Madrid
- Intervention
- Cetuximab(drug)
- Enrollment
- 65 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (11)
- Instituto Catalán de Oncología - Hospital Duran i Reynals, Barcelona, Barcelona, Spain
- Hospital Universitario Marqués de Valdecilla (Santander), Santander, Cantabria, Spain
- Centro Oncológico de Galicia (La Coruña), A Coruña, La Coruña, Spain
- Hospital Clínico San Carlos, Madrid, Madrid, Spain
- Hospital Universitario 12 de Octubre (Madrid), Madrid, Madrid, Spain
- Hospital Infanta Leonor (Madrid), Vallecas, Madrid, Spain
- Complejo Hospitalario de Navarra (Pamplona), Pamplona, Navarre, Spain
- Complejo Hospitalario de Salamanca (Salamanca), Salamanca, Salamanca, Spain
- Hospital Universitario de Canarias (La laguna), San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
- Hospital Universitario Virgen del Rocío (Sevilla), Seville, Sevilla, Spain
- Hospital Universitario Virgen de Valme (Sevilla), Seville, Sevilla, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06856213 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →